GRTS Profile
Gritstone Bio Inc. (GRTS) is a clinical-stage biotechnology company that develops personalized cancer immunotherapies using its proprietary EDGE (Epitope-Specific Immunotherapy for Cancer) platform. The platform utilizes machine learning algorithms to identify and select specific tumor-specific mutations, or neoantigens, that can be targeted by the immune system. Gritstone Bio's lead product candidate, GRANITE-001, is a personalized neoantigen-based immunotherapy for the treatment of solid tumors that is currently in Phase 2 clinical trials. The company is also developing SLATE-001, a neoantigen-based immunotherapy for the treatment of cancers caused by human papillomavirus (HPV). Gritstone Bio is headquartered in Emeryville, California. As of September 2021, the company had a market capitalization of approximately $480 million.
|
